Arcutis Biotherapeutics, Inc.
ARQT
Pozycja w akcjach
#4008
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Cena akcji
$32.29
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$4.06B
Zmiana (1 dzień)
12.02%
Zmiana (1 rok)
54.62%
Kraj
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)
Kategoria
Healthcare
Zyski dla Arcutis Biotherapeutics, Inc. (ARQT)
Zyski w Jun 2026 TTM: $29.30M
Według najnowszych raportów finansowych Arcutis Biotherapeutics, Inc., obecny zysk firmy wynosi $29.30M. W roku 2023 firma osiągnęła zysk w wysokości $-259.03M, wzrost w porównaniu do zysku z roku 2022, który wynosił $-311.46M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Arcutis Biotherapeutics, Inc. od 2017 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $29.30M | -121.02% |
| 2024 | $-139.39M | -46.19% |
| 2023 | $-259.03M | -16.83% |
| 2022 | $-311.46M | 50.93% |
| 2021 | $-206.36M | 52.09% |
| 2020 | $-135.68M | 223.07% |
| 2019 | $-42.00M | 118.10% |
| 2018 | $-19.26M | 286.80% |
| 2017 | $-4.98M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | 17,904.30% |
US
|
|
| $-3.09B | -10,636.56% |
US
|
|
| $-4.02B | -13,808.09% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 6,557.96% |
NL
|
